OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi Results

OncoDaily Academy Is Now Live: Free Global Oncology Education Starts Today

Japan Approves Zongertinib for First-Line Treatment of HER2-Mutant Advanced NSCLC

Expert Discussion at COGC 2026: What Community Oncology Should Look Like by 2030

Eva Compérat: Why Molecular Pathology Is Essential in Kidney Cancer Care

KHCC Recognizes Arab Researchers for Outstanding Contributions to Cancer Research at 2026 Awards

Beyond Tumor Stage: Nature Cancer Study Maps the Hidden Cellular Drivers of Lung Cancer Metastasis

Acute Myeloid Leukemia: Genetic Origins May Trace Back Decades Before Diagnosis

Immune Oncology

OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.